Immunological checkpoint inhibitors enter adolescence
Mené sur 29 patients atteints d'un mésothéliome malin de stade avancé, cet essai italien de phase II évalue l'efficacité, du point de vue de la proportion de patients avec une réponse objective complète ou partielle, et la toxicité du tremelimumab, un anticorps monoclonal anti CTLA4
Immunological checkpoint inhibitors were first used in the oncology clinic for treatment of melanoma, and have recently consolidated their position as a key therapeutic strategy—regulatory approval exists for ipilimumab in many health-care systems. Unlike adoptive immunotherapy or vaccination strategies, this class of agent does not require autologous lymphocytes, tumour, or known tumour antigens, which are requirements that previously restricted the application of immunotherapy to some tumour...
The Lancet Oncology , commentaire, 2012